



Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Selected for Presentation at the ARVO 2009 Annual Meeting

LEXINGTON Mass.,-- April 28, 2009 – Inotek Pharmaceuticals today announced that preclinical data supporting the Company's lead clinical-stage drug candidate in glaucoma, INO-8875, will be presented in a poster session at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2009 Annual Meeting in Fort Lauderdale, FL. INO-8875 is a highly selective adenosine-1 receptor agonist currently completing a Phase 1/2 trial as a topical agent for the treatment of elevated intraocular pressure (IOP) associated with primary open angle glaucoma and ocular hypertension. The preclinical data suggests that INO-8875 lowers IOP primarily by restoring trabecular meshwork outflow, the most important outflow pathway to maintain IOP in healthy eyes. Additionally, INO-8875 may have a secondary mechanism of action to decrease IOP by reducing aqueous humor production.

Norman Kim, M.S., DABT, Senior Director, Preclinical Development at Inotek will present the results of Abstract #4061/A223 entitled "INO-8875, An Adenosine A1 Agonist, in Development for Open-Angle Glaucoma Reduces IOP in Three Rabbit Models" on Wednesday, May 06, 2009 at 8:30 AM ET.

About Inotek Pharmaceuticals

Inotek is a clinical-stage pharmaceutical company developing ophthalmic therapies with novel mechanisms of action to address significant diseases of the eye. The Company has an emerging pipeline of drug candidates targeting a broad range of ophthalmic diseases, including glaucoma, age-related macular degeneration, and diabetic retinopathy.

###

Media Relations:

Sarah Cavanaugh

MacDougall Biomedical Communications

scavanaugh@macbiocom.com

(781) 235-3060